Versant Ventures closes new $305 mln fund with help of Canadian LPs
U.S. venture capital firm Versant Ventures has closed Versant Venture Capital V LP at US$305 million, surpassing its initial target of US$250 million. The fund will invest across the global healthcare sector and at all stages of company development. Versant, which has an office in Vancouver, has received capital commitments for Fund V from a number of Canadian institutional investors, including BDC Capital, Fonds de solidarité FTQ, Northleaf Venture Catalyst Fund and Teralys Capital. This support owed to Versant’s current and planned activity in developing Canada’s life sciences ecosystem.
10 December 2014•3 mins read
